Once-Weekly Semaglutide in Adults with Overweight or Obesity

Cited by (1,089)

Items 101–200 of 1,089

1. Menopause: a cardiometabolic transition
   Rossella E Nappi, Peter Chedraui, Irene V. Lambrinoudaki, Tommaso Simoncini · 2022 · The Lancet Diabetes & Endocrinology
2. 100 years of insulin: celebrating the past, present and future of diabetes therapy
   Sims, Emily K., Carr, Alice L. J., Oram, Richard A., DiMeglio, Linda A., Evans-Molina, Carmella · 2021 · Nature Medicine
3. Clinical management and treatment of obesity in China
   Zeng, Qiang, Li, Naishi, Pan, Xiong-Fei, Chen, Lulu, Pan, An · 2021 · The Lancet Diabetes & Endocrinology
4. Mechanisms of action and therapeutic applications of GLP-1 and dual GIP/GLP-1 receptor agonists
   Liu, Qiyuan Keith · 2024 · Frontiers in Endocrinology
5. Semaglutide for the treatment of overweight and obesity: A review
   Bergmann, Natasha Chidekel, Davies, Melanie J., Lingvay, Ildiko, Knop, Filip K. · 2023 · Diabetes, Obesity and Metabolism
6. Medications for Obesity: A Review
   Gudzune, Kimberly A., Kushner, Robert F. · 2024 · JAMA
7. An unbiased ranking of murine dietary models based on their proximity to human metabolic dysfunction-associated steatotic liver disease (MASLD)
   Vacca, Michele, Kamzolas, Ioannis, Harder, Lea Mørch, Oakley, Fiona, Trautwein, Christian, Hatting, Maximilian, Ross, Trenton, Bernardo, Barbara, Oldenburger, Anouk, Hjuler, Sara Toftegaard et al. · 2024 · Nature Metabolism
8. Estimated Burden of Metabolic Dysfunction–Associated Steatotic Liver Disease in US Adults, 2020 to 2050
   Phuc Le, Moosa Tatar, Srinivasan Dasarathy, Naim Alkhouri, William H. Herman, Glen B. Taksler, Abhishek Deshpande, Wen Ye, Olajide A. Adekunle, Arthur J. McCullough et al. · 2025 · JAMA Network Open
9. GLP−1 receptor agonists for the treatment of obesity: Role as a promising approach
   Wang, Jing-Yue, Wang, Quan-Wei, Yang, Xin-Yu, Yang, Wei, Li, Dong-Rui, Jin, Jing-Yu, Zhang, Hui-Cong, Zhang, Xian-Feng · 2023 · Frontiers in Endocrinology
10. Association of semaglutide with risk of suicidal ideation in a real-world cohort
    Wang, William, Volkow, Nora D., Berger, Nathan A., Davis, Pamela B., Kaelber, David C., Xu, Rong · 2024 · Nature Medicine
11. Weight-Loss Strategies for Prevention and Treatment of Hypertension: A Scientific Statement From the American Heart Association
    Michael E. Hall, Jordana B. Cohen, Jamy D. Ard, Brent M. Egan, John Edward Hall, Carl J. Lavie, Jun Ma, Chiadi E. Ndumele, Philip R. Schauer, Daichi Shimbo · 2021 · Hypertension
12. The melanocortin pathway and energy homeostasis: From discovery to obesity therapy
    Giles S.H. Yeo, Daniela Herrera Moro Chao, Anna‐Maria Siegert, Zoe M. Koerperich, Mark D. Ericson, Stephanie E. Simonds, Courtney M. Larson, Serge H. Luquet, Iain James Clarke, Shubh D. Sharma et al. · 2021 · Molecular Metabolism
13. Beyond the pancreas: contrasting cardiometabolic actions of GIP and GLP1
    Hammoud, Rola, Drucker, Daniel J. · 2023 · Nature Reviews Endocrinology
14. The expanding incretin universe: from basic biology to clinical translation
    Drucker, Daniel J., Holst, Jens J. · 2023 · Diabetologia
15. Effect of glucagon-like peptide-1 receptor agonists and co-agonists on body composition: Systematic review and network meta-analysis
    Karakasis, Paschalis, Patoulias, Dimitrios, Fragakis, Nikolaos, Mantzoros, Christos S. · 2025 · Metabolism
16. Excess body weight: Novel insights into its roles in obesity comorbidities
    Xiang Zhang, Suki Ha, Harry Cheuk-Hay Lau, Jun Qing Yu · 2023 · Seminars in Cancer Biology
17. Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity.
    Garvey, W. Timothy, Blüher, Matthias, Osorto Contreras, Cynthia Karenina, Davies, Melanie J., Winning Lehmann, Eva, Pietiläinen, Kirsi H., Rubino, Domenica, Sbraccia, Paolo, Wadden, Thomas, Zeuthen, Niels et al. · 2025 · New England Journal of Medicine
18. Weight Loss Outcomes Associated With Semaglutide Treatment for Patients With Overweight or Obesity
    Ghusn, Wissam, De la Rosa, Alan, Sacoto, Daniel, Cifuentes, Lizeth, Campos, Alejandro, Feris, Fauzi, Hurtado, Maria Daniela, Acosta, Andres · 2022 · JAMA Network Open
19. Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial
    le Roux, Carel W, Steen, Oren, Lucas, Kathryn J, Startseva, Elena, Unseld, Anna, Hennige, Anita M · 2024 · The Lancet Diabetes & Endocrinology
20. Managing the gastrointestinal side effects of GLP-1 receptor agonists in obesity: recommendations for clinical practice
    Wharton, Sean, Davies, Melanie, Dicker, Dror, Lingvay, Ildiko, Mosenzon, Ofri, Rubino, Domenica M., Pedersen, Sue D. · 2022 · Postgraduate Medicine
21. Efficacy of peroxisome proliferator-activated receptor agonists, glucagon-like peptide-1 receptor agonists, or sodium-glucose cotransporter-2 inhibitors for treatment of non-alcoholic fatty liver disease: A systematic review
    Mantovani, Alessandro, Byrne, Christopher D, Targher, Giovanni · 2022 · The Lancet Gastroenterology & Hepatology
22. Safety and efficacy of combination therapy with semaglutide, cilofexor and firsocostat in patients with non-alcoholic steatohepatitis: A randomised, open-label phase II trial
    Alkhouri, Naim, Herring, Robert, Kabler, Heidi, Kayali, Zeid, Hassanein, Tarek, Kohli, Anita, Huss, Ryan S., Zhu, Yanni, Billin, Andrew N., Damgaard, Lars Holm et al. · 2022 · Journal of Hepatology
23. Semaglutide for the treatment of obesity
    Chao, Ariana M., Tronieri, Jena S., Amaro, Anastassia, Wadden, Thomas A. · 2023 · Trends in Cardiovascular Medicine
24. Resmetirom therapy for metabolic dysfunction-associated steatotic liver disease: October 2024 updates to AASLD Practice Guidance
    Vincent Lingzhi Chen, Timothy R.M. Morgan, Yaron Rotman, Heather M. Patton, Kenneth J. Cusi, Fasiha Kanwal, W. Ray Kim · 2024 · Hepatology
25. Randomised clinical trial: semaglutide versus placebo reduced liver steatosis but not liver stiffness in subjects with non‐alcoholic fatty liver disease assessed by magnetic resonance imaging
    Flint, Anne, Andersen, Grit, Hockings, Paul, Johansson, Lars, Morsing, Anni, Sundby Palle, Mads, Vogl, Thomas, Loomba, Rohit, Plum‐Mörschel, Leona · 2021 · Alimentary Pharmacology & Therapeutics
26. A GIPR antagonist conjugated to GLP-1 analogues promotes weight loss with improved metabolic parameters in preclinical and phase 1 settings
    Véniant, Murielle M., Lu, Shu-Chen, Atangan, Larissa, Komorowski, Renee, Stanislaus, Shanaka, Cheng, Yuan, Wu, Bin, Falsey, James R., Hager, Todd, Thomas, Veena A. et al. · 2024 · Nature Metabolism
27. Efficacy of GLP-1 RA Approved for Weight Management in Patients With or Without Diabetes: A Narrative Review
    Jensterle, Mojca, Rizzo, Manfredi, Haluzík, Martin, Janež, Andrej · 2022 · Advances in Therapy
28. An overview of obesity‐related complications: The epidemiological evidence linking body weight and other markers of obesity to adverse health outcomes
    Matthias Blüher · 2025 · Diabetes Obesity and Metabolism
29. The glucagon-like peptide-1 (GLP-1) analogue semaglutide reduces alcohol drinking and modulates central GABA neurotransmission
    Chuong, Vicky, Farokhnia, Mehdi, Khom, Sophia, Pince, Claire L., Elvig, Sophie K., Vlkolinsky, Roman, Marchette, Renata C.N., Koob, George F., Roberto, Marisa, Vendruscolo, Leandro F. et al. · 2023 · JCI Insight
30. Public interest in the off-label use of glucagon-like peptide 1 agonists (Ozempic) for cosmetic weight loss: a Google trends analysis.
    Han, Sabrina H, Safeek, Rachel, Ockerman, Kyle, Trieu, Nhan, Mars, Patricia, Klenke, Audrey, Furnas, Heather, Sorice-Virk, Sarah · 2023 · Aesthetic Surgery Journal
31. 3. Prevention or Delay of Diabetes and Associated Comorbidities: Standards of Care in Diabetes—2023
    Nuha A. ElSayed, Grazia Aleppo, Vanita R. Aroda, Raveendhara R. Bannuru, Florence M. Brown, Dennis Bruemmer, Billy S. Collins, Jason L. Gaglia, Marisa E. Hilliard, Diana M. Isaacs et al. · 2022 · Diabetes Care
32. Real‐world evidence on the utilization, clinical and comparative effectiveness, and adverse effects of newer GLP ‐ 1RA ‐based weight‐loss therapies
    Thomsen, Reimar W., Mailhac, Aurélie, Løhde, Julie B., Pottegård, Anton · 2025 · Diabetes Obesity and Metabolism
33. Healthy weight loss maintenance with exercise, GLP-1 receptor agonist, or both combined followed by one year without treatment: a post-treatment analysis of a randomised placebo-controlled trial
    Jensen, Simon Birk Kjær, Blond, Martin Bæk, Sandsdal, Rasmus Michael, Olsen, Lisa Møller, Juhl, Christian Rimer, Lundgren, Julie Rehné, Janus, Charlotte, Stallknecht, Bente Merete, Holst, Jens Juul, Madsbad, Sten et al. · 2024 · eClinicalMedicine
34. Semaglutide, delayed gastric emptying, and intraoperative pulmonary aspiration: a case report
    Klein, Sandra R., Hobai, Ion A. · 2023 · Canadian Journal of Anesthesia/Journal canadien d'anesthésie
35. A review of current guidelines for the treatment of obesity
    2022 · The American Journal of Managed Care
36. Polycystic ovary syndrome: a “risk-enhancing” factor for cardiovascular disease
    Carolyn S. Guan, Salman Zahid, Anum Sohail Minhas, Pamela Ouyang, Arthur “Jason” J. Vaught, Valerie Lynn Baker, Erin D. Michos · 2022 · Fertility and Sterility
37. Patient Phenotype Profiling in Heart Failure with Preserved Ejection Fraction to Guide Therapeutic Decision Making. A Scientific Statement of the Heart Failure Association, the European Heart Rhythm Association of the European Society of Cardiology, and the European Society of Hypertension
    Stefan D. Anker, Muhammad Usman, Markus S. Anker, Javed Butler, Michael Böhm, William T. Abraham, Marianna Adamo, Vijay Chopra, Mariantonietta Cicoira, Francesco Cosentino et al. · 2023 · European Journal of Heart Failure
38. LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial
    Urva, Shweta, Coskun, Tamer, Loh, Mei Teng, Du, Yu, Thomas, Melissa K, Gurbuz, Sirel, Haupt, Axel, Benson, Charles T, Hernandez-Illas, Martha, D’Alessio, David A et al. · 2022 · The Lancet
39. Effects of liraglutide on visceral and ectopic fat in adults with overweight and obesity at high cardiovascular risk: a randomised, double-blind, placebo-controlled, clinical trial
    Neeland, Ian J, Marso, Steven P, Ayers, Colby R, Lewis, Bienka, Oslica, Robert, Francis, Wynona, Rodder, Susan, Pandey, Ambarish, Joshi, Parag H · 2021 · The Lancet Diabetes & Endocrinology
40. Gastrointestinal tolerability of once‐weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss
    Wharton, Sean, Calanna, Salvatore, Davies, Melanie, Dicker, Dror, Goldman, Bryan, Lingvay, Ildiko, Mosenzon, Ofri, Rubino, Domenica M., Thomsen, Mette, Wadden, Thomas A. et al. · 2022 · Diabetes, Obesity and Metabolism
41. The Related Metabolic Diseases and Treatments of Obesity
    Ming Jun Yang, Shuai Liu, Chunye Zhang · 2022 · Healthcare
42. Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment
    Wharton, Sean, Aronne, Louis J., Stefanski, Adam, Alfaris, Nasreen F., Ciudin, Andreea, Yokote, Koutaro, Halpern, Bruno, Shukla, Alpana P., Zhou, Chunmei, Macpherson, Lisa et al. · 2025 · New England Journal of Medicine
43. Obesity in South and Southeast Asia—A new consensus on care and management
    Tham, Kwang Wei, Abdul Ghani, Rohana, Cua, Sioksoan C., Deerochanawong, Chaicharn, Fojas, Mia, Hocking, Samantha, Lee, June, Nam, Tran Quang, Pathan, Faruque, Saboo, Banshi et al. · 2023 · Obesity Reviews
44. The impact of population ageing on the burden of chronic kidney disease
    Nicholas C Chesnaye, Alberto Ortíz, Carmine Zoccali, Vianda S Stel, Kitty J. Jager · 2024 · Nature Reviews Nephrology
45. Body composition changes during weight reduction with tirzepatide in the SURMOUNT ‐1 study of adults with obesity or overweight
    Look, Michelle, Dunn, Julia P., Kushner, Robert F., Cao, Dachuang, Harris, Charles, Gibble, Theresa Hunter, Stefanski, Adam, Griffin, Ryan · 2025 · Diabetes, Obesity and Metabolism
46. Muscle Mass and Glucagon-Like Peptide-1 Receptor Agonists: Adaptive or Maladaptive Response to Weight Loss?
    Linge, Jennifer, Birkenfeld, Andreas L., Neeland, Ian J. · 2024 · Circulation
47. Diets and drugs for weight loss and health in obesity – An update
    Jan Aaseth, Stian Ellefsen, Urban Alehagen, Tine Mejlbo Sundfør, Jan Alexander · 2021 · Biomedicine & Pharmacotherapy
48. Effect of glucagon-like peptide-1 receptor agonists on body weight in adults with obesity without diabetes mellitus—a systematic review and meta-analysis of randomized control trials
    Iqbal, Junaid, Wu, Hui‐Xuan, Hu, Nan, Zhou, Ying‐Hui, Li, Long, Xiao, Fen, Wang, Ting, Jiang, Hong‐Li, Xu, Shi‐Na, Huang, Bi‐Ling et al. · 2022 · Obesity Reviews
49. Safety and Efficacy of Liraglutide, 3.0 mg, Once Daily vs Placebo in Patients With Poor Weight Loss Following Metabolic Surgery: The BARI-OPTIMISE Randomized Clinical Trial
    Mok, Jessica, Adeleke, Mariam O., Brown, Adrian, Magee, Cormac G., Firman, Chloe, Makahamadze, Christwishes, Jassil, Friedrich C., Marvasti, Parastou, Carnemolla, Alisia, Devalia, Kalpana et al. · 2023 · JAMA Surgery
50. Obesity and diabetes
    Chrysoula Boutari, Antea J. DeMarsilis, Christos Socrates Mantzoros · 2023 · Diabetes Research and Clinical Practice
51. Genomics and phenomics of body mass index reveals a complex disease network
    Huang, Jie, Huffman, Jennifer E., Huang, Yunfeng, Do Valle, Ítalo, Assimes, Themistocles L., Raghavan, Sridharan, Voight, Benjamin F., Liu, Chang, Barabási, Albert-László, Huang, Rose D. L. et al. · 2022 · Nature Communications
52. Sex- and Gender-Related Differences in Obesity: From Pathophysiological Mechanisms to Clinical Implications
    Andrijana Koceva, Rok Herman, Andrej Janež, Matej Rakuša, Mojca Jensterle · 2024 · International Journal of Molecular Sciences
53. Dissociable hindbrain GLP1R circuits for satiety and aversion
    Huang, Kuei-Pin, Acosta, Alisha A., Ghidewon, Misgana Y., McKnight, Aaron D., Almeida, Milena S., Nyema, Nathaniel T., Hanchak, Nicholas D., Patel, Nisha, Gbenou, Yenoukoume S. K., Adriaenssens, Alice E. et al. · 2024 · Nature
54. Hypertension Related to Obesity: Pathogenesis, Characteristics and Factors for Control
    Paul Meouchy, Mohamad Wahoud, Sabine Allam, Roy Chedid, Wissam Karam, Sabine Karam · 2022 · International Journal of Molecular Sciences
55. Therapeutic targets, novel drugs, and delivery systems for diabetes associated NAFLD and liver fibrosis
    Virender Kumar, Xiaofei Xin, Jingyi Ma, Chalet Tan, Natalia A. Osna, Ram I. Mahato · 2021 · Advanced Drug Delivery Reviews
56. Prevalence, risk factors, and interventions for obesity in Saudi Arabia: A systematic review
    Victoria Salem, Noara Khaled Alhusseini, Habeeb Ibrahim Abdul Razack, Anastasia Naoum, Omar T. Sims, Saleh A. Alqahtani · 2022 · Obesity Reviews
57. Obesity and psychological distress
    Andrew Steptoe, Philipp Frank · 2023 · Philosophical Transactions of the Royal Society B Biological Sciences
58. Effect of Time-Restricted Eating on Weight Loss in Adults With Type 2 Diabetes
    Vasiliki Pavlou, Sofia Cienfuegos, Shuhao Lin, Mark Ezpeleta, Kathleen A. Ready, Sarah Corapi, Jackie Q. Wu, Jason Lopez, Kelsey Gabel, Lisa Marie Tussing-Humphreys et al. · 2023 · JAMA Network Open
59. The Emerging Role of Glucagon-like Peptide-1 Receptor Agonists for the Management of NAFLD
    Chandani Patel Chavez, Kenneth J. Cusi, Sushma Kadiyala · 2021 · The Journal of Clinical Endocrinology & Metabolism
60. Efficacy of the Glucagon-Like Peptide-1 Receptor Agonists Liraglutide and Semaglutide for the Treatment of Weight Regain After Bariatric surgery: a Retrospective Observational Study
    Jensen, Anders Boisen, Renström, Frida, Aczél, Stefan, Folie, Patrick, Biraima-Steinemann, Magdalena, Beuschlein, Felix, Bilz, Stefan · 2023 · Obesity Surgery
61. 3. Prevention or Delay of Diabetes and Associated Comorbidities: Standards of Care in Diabetes—2025
    Nuha A. ElSayed, Rozalina G. McCoy, Grazia Aleppo, Kirthikaa Balapattabi, Elizabeth Ann Beverly, Kathaleen Briggs Early, Dennis Bruemmer, Osagie A. Ebekozien, Justin Basile Echouffo-Tcheugui, Laya Ekhlaspour et al. · 2024 · Diabetes Care
62. Are people with metabolically healthy obesity really healthy? A prospective cohort study of 381,363 UK Biobank participants
    Ziyi Zhou, John Macpherson, Stuart Robert Gray, Jason M. R. Gill, Paul I. Welsh, Carlos A. Celis-Morales, Naveed A. Sattar, Jill P. Pell, Frederick Ka Wing Ho · 2021 · Diabetologia
63. Obstructive sleep apnea and obesity: A review of epidemiology, pathophysiology and the effect of weight-loss treatments
    Ludovico Messineo, Jessie P. Bakker, John Cronin, John Yee, David P. White · 2024 · Sleep Medicine Reviews
64. Semaglutide reduces alcohol intake and relapse-like drinking in male and female rats
    Aranäs, Cajsa, Edvardsson, Christian E., Shevchouk, Olesya T., Zhang, Qian, Witley, Sarah, Blid Sköldheden, Sebastian, Zentveld, Lindsay, Vallöf, Daniel, Tufvesson-Alm, Maximilian, Jerlhag, Elisabet · 2023 · eBioMedicine
65. New insights into the treatment of obesity
    Blüher, Matthias, Aras, Mohini, Aronne, Louis J., Batterham, Rachel L., Giorgino, Francesco, Ji, Linong, Pietiläinen, Kirsi H., Schnell, Oliver, Tonchevska, Elena, Wilding, John P.H. · 2023 · Diabetes, Obesity and Metabolism
66. New Frontiers in Obesity Treatment: GLP-1 and Nascent Nutrient-Stimulated Hormone-Based Therapeutics
    Jastreboff, Ania M., Kushner, Robert F. · 2023 · Annual Review of Medicine
67. The expanding role of GLP-1 receptor agonists: a narrative review of current evidence and future directions
    Moiz, Areesha, Filion, Kristian B., Tsoukas, Michael A., Yu, Oriana H.Y., Peters, Tricia M., Eisenberg, Mark J. · 2025 · EClinicalMedicine
68. Obesity and its comorbidities, current treatment options and future perspectives: Challenging bariatric surgery?
    Simon Kloock, Christian G. Ziegler, Ulrich Dischinger · 2023 · Pharmacology & Therapeutics
69. Bone Health After Exercise Alone, GLP-1 Receptor Agonist Treatment, or Combination Treatment: A Secondary Analysis of a Randomized Clinical Trial
    Jensen, Simon Birk Kjær, Sørensen, Victor, Sandsdal, Rasmus Michael, Lehmann, Eva Winning, Lundgren, Julie Rehné, Juhl, Christian Rimer, Janus, Charlotte, Ternhamar, Tummas, Stallknecht, Bente Merete, Holst, Jens Juul et al. · 2024 · JAMA Network Open
70. Acts of appetite: neural circuits governing the appetitive, consummatory, and terminating phases of feeding
    Alcantara, Ivan C., Tapia, Ana Pamela Miranda, Aponte, Yeka, Krashes, Michael J. · 2022 · Nature Metabolism
71. Pharmacotherapy for adults with overweight and obesity: a systematic review and network meta-analysis of randomised controlled trials
    Shi, Qingyang, Wang, Yang, Hao, Qiukui, Vandvik, Per Olav, Guyatt, Gordon, Li, Jing, Chen, Zhe, Xu, Shishi, Shen, Yanjiao, Ge, Long et al. · 2024 · The Lancet
72. Effects of dietary fibre on metabolic health and obesity
    Edward C. Deehan, Valentin Mocanu, Karen L. Madsen · 2024 · Nature Reviews Gastroenterology & Hepatology
73. Brain GLP-1 and the regulation of food intake: GLP-1 action in the brain and its implications for GLP-1 receptor agonists in obesity treatment
    Trapp, Stefan, Brierley, Daniel I. · 2022 · British Journal of Pharmacology
74. Nutritional priorities to support GLP-1 therapy for obesity: a joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society
    Mozaffarian, Dariush, Agarwal, Monica, Aggarwal, Monica, Alexander, Lydia, Apovian, Caroline M, Bindlish, Shagun, Bonnet, Jonathan, Butsch, W Scott, Christensen, Sandra, Gianos, Eugenia et al. · 2025 · The American Journal of Clinical Nutrition
75. Regurgitation under anesthesia in a fasted patient prescribed semaglutide for weight loss: a case report
    Gulak, Michael A., Murphy, Patricia · 2023 · Canadian Journal of Anesthesia/Journal canadien d'anesthésie
76. Incretin-Based Weight Loss Pharmacotherapy: Can Resistance Exercise Optimize Changes in Body Composition?
    Locatelli, João Carlos, Costa, Juliene Gonçalves, Haynes, Andrew, Naylor, Louise H., Fegan, P. Gerry, Yeap, Bu B., Green, Daniel J. · 2024 · Diabetes Care
77. Efficacy and Safety of Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss Among Adults Without Diabetes
    Moiz, Areesha, Filion, Kristian B., Toutounchi, Helia, Tsoukas, Michael A., Yu, Oriana H.Y., Peters, Tricia M., Eisenberg, Mark J. · 2025 · Annals of Internal Medicine
78. Strategies for minimizing muscle loss during use of incretin‐mimetic drugs for treatment of obesity
    Mechanick, Jeffrey I., Butsch, W. Scott, Christensen, Sandra M., Hamdy, Osama, Li, Zhaoping, Prado, Carla M., Heymsfield, Steven B. · 2025 · Obesity Reviews
79. Structural insights into multiplexed pharmacological actions of tirzepatide and peptide 20 at the GIP, GLP-1 or glucagon receptors
    Zhao, Fenghui, Zhou, Qingtong, Cong, Zhaotong, Hang, Kaini, Zou, Xinyu, Zhang, Chao, Chen, Yan, Dai, Antao, Liang, Anyi, Ming, Qianqian et al. · 2022 · Nature Communications
80. GIPR/GLP-1R dual agonist therapies for diabetes and weight loss—chemistry, physiology, and clinical applications
    Campbell, Jonathan E., Müller, Timo D., Finan, Brian, DiMarchi, Richard D., Tschöp, Matthias H., D’Alessio, David A. · 2023 · Cell Metabolism
81. Using genetic association data to guide drug discovery and development: Review of methods and applications
    Stephen Burgess, Amy M. Mason, Andrew J. Grant, Eric A. W. Slob, Apostolos Gkatzionis, Verena Zuber, Ashish R Patel, Haodong Tian, Cunhao Liu, William Geoffrey Haynes et al. · 2023 · The American Journal of Human Genetics
82. Next generation GLP-1/GIP/glucagon triple agonists normalize body weight in obese mice
    Knerr, Patrick J., Mowery, Stephanie A., Douros, Jonathan D., Premdjee, Bhavesh, Hjøllund, Karina Rahr, He, Yantao, Kruse Hansen, Ann Maria, Olsen, Anette K., Perez-Tilve, Diego, DiMarchi, Richard D. et al. · 2022 · Molecular Metabolism
83. Brain-wide cell-type-specific transcriptomic signatures of healthy ageing in mice
    Kelly Jin, Zizhen Yao, Cindy T. J. van Velthoven, Eitan S Kaplan, Katie J. Glattfelder, Samuel T. Barlow, Gabriella Boyer, Daniel Carey, Tamara Casper, Anish Bhaswanth Chakka et al. · 2025 · Nature
84. Recent Advances in Incretin-Based Pharmacotherapies for the Treatment of Obesity and Diabetes
    Tan, Qiming, Akindehin, Seun E., Orsso, Camila E., Waldner, Richelle C., DiMarchi, Richard D., Müller, Timo D., Haqq, Andrea M. · 2022 · Frontiers in Endocrinology
85. 3. Prevention or Delay of Diabetes and Associated Comorbidities: Standards of Care in Diabetes—2024
    Nuha A. ElSayed, Grazia Aleppo, Raveendhara R. Bannuru, Dennis Bruemmer, Billy S. Collins, Laya Ekhlaspour, Jason L. Gaglia, Marisa E. Hilliard, Eric L. Johnson, Kamlesh Khunti et al. · 2023 · Diabetes Care
86. Gastrointestinal adverse events associated with semaglutide: A pharmacovigilance study based on FDA adverse event reporting system
    Shu, Yamin, He, Xucheng, Wu, Pan, Liu, Yanxin, Ding, Yufeng, Zhang, Qilin · 2022 · Frontiers in Public Health
87. Role of immune responses in the development of NAFLD-associated liver cancer and prospects for therapeutic modulation
    Neda Yahoo, Michael Dudek, Percy Alexander Knolle, Mathias F Heikenwälder · 2023 · Journal of Hepatology
88. Systematic Review and Meta-Analysis of the Impact of Bariatric Surgery on Future Cancer Risk
    Wilson, Robert B., Lathigara, Dhruvi, Kaushal, Devesh · 2023 · International Journal of Molecular Sciences
89. Nutritional priorities to support GLP ‐1 therapy for obesity: A joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society
    Mozaffarian, Dariush, Agarwal, Monica, Aggarwal, Monica, Alexander, Lydia, Apovian, Caroline M., Bindlish, Shagun, Bonnet, Jonathan, Butsch, W. Scott, Christensen, Sandra, Gianos, Eugenia et al. · 2025 · Obesity
90. Cagrilintide–Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes
    Davies, Melanie J., Bajaj, Harpreet S., Broholm, Christa, Eliasen, Astrid, Garvey, W. Timothy, le Roux, Carel W., Lingvay, Ildiko, Lyndgaard, Christian Bøge, Rosenstock, Julio, Pedersen, Sue D. · 2025 · New England Journal of Medicine
91. The risk of depression, anxiety, and suicidal behavior in patients with obesity on glucagon like peptide-1 receptor agonist therapy
    Kornelius, Edy, Huang, Jing-Yang, Lo, Shih-Chang, Huang, Chien-Ning, Yang, Yi-Sun · 2024 · Scientific Reports
92. From Cardiovascular-Kidney-Metabolic Syndrome to Cardiovascular-Renal-Hepatic-Metabolic Syndrome: Proposing an Expanded Framework
    Nikolaos Theodorakis, Maria Nikolaou · 2025 · Biomolecules
93. The impact of weight loss on fat-free mass, muscle, bone and hematopoiesis health: Implications for emerging pharmacotherapies aiming at fat reduction and lean mass preservation
    Stefanakis, Konstantinos, Kokkorakis, Michail, Mantzoros, Christos S. · 2024 · Metabolism
94. Beyond appetite regulation: Targeting energy expenditure, fat oxidation, and lean mass preservation for sustainable weight loss
    Christoffersen, Berit Østergaard, Sanchez‐Delgado, Guillermo, John, Linu Mary, Ryan, Donna H., Raun, Kirsten, Ravussin, Eric · 2022 · Obesity
95. Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity
    Wharton, Sean, Lingvay, Ildiko, Bogdanski, Pawel, Duque do Vale, Ruben, Jacob, Stephan, Karlsson, Tobias, Shaji, Chaithra, Rubino, Domenica, Garvey, W. Timothy · 2025 · New England Journal of Medicine
96. American Association of Clinical Endocrinology Consensus Statement: Algorithm for the Evaluation and Treatment of Adults with Obesity/Adiposity-Based Chronic Disease – 2025 Update
    Nadolsky, Karl, Garvey, W. Timothy, Agarwal, Monica, Bonnecaze, Alex, Burguera, Bartolome, Chaplin, Michelle DeGeeter, Griebeler, Marcio L., Harris, Samantha R., Schellinger, Jeffrey N., Simonetti, Juliana et al. · 2025 · Endocrine Practice
97. Comparative effectiveness of glucagon‐like peptide‐1 receptor agonists for the management of obesity in adults without diabetes: A network meta‐analysis of randomized clinical trials
    Alkhezi, Omar S., Alahmed, Abdullah A., Alfayez, Osamah M., Alzuman, Osama A., Almutairi, Abdulaali R., Almohammed, Omar A. · 2023 · Obesity Reviews
98. Epidemiology of Diabetes and Atherosclerotic Cardiovascular Disease Among Asian American Adults: Implications, Management, and Future Directions: A Scientific Statement From the American Heart Association
    Tak Kwan, Sally Sukman Wong, Yuling Hong, Alka M. Kanaya, Sadiya S. Khan, Laura Lucia Hayman, Svati Hasmukh Shah, Francine K. Welty, PRAKASH C. DEEDWANIA, Asma Khaliq et al. · 2023 · Circulation
99. Dose-response effects on HbA1c and bodyweight reduction of survodutide, a dual glucagon/GLP-1 receptor agonist, compared with placebo and open-label semaglutide in people with type 2 diabetes: a randomised clinical trial
    Blüher, Matthias, Rosenstock, Julio, Hoefler, Josef, Manuel, Raymond, Hennige, Anita M. · 2024 · Diabetologia
100. Efficacy and Safety of Tirzepatide in Type 2 Diabetes and Obesity Management
     Sinha, Rachel, Papamargaritis, Dimitris, Sargeant, Jack A., Davies, Melanie J. · 2023 · Journal of Obesity & Metabolic Syndrome